Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Joyzyme GroupHKSE:08622 +3.13%40 Days Payable is 19.86 as of Dec. 2025, which is 54% below its 10-year median of 42.72. GuruFocus rates HKSE:08622 with a GF Score™ of 40/100 and a GF Value™ of HK$0.17 (Fairly Valued). The stock has 4 warning signs investors should review. Among 925 Drug Manufacturers companies, Joyzyme Group ranks worse than 93.08% on this metric.
The historical data trend for Joyzyme Group's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Joyzyme Group's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Joyzyme Group Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Joyzyme Group's Days Payable distribution charts can be found below:
* The bar in red indicates where Joyzyme Group's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Joyzyme Group's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Joyzyme Group (HKSE:08622) has a Days Payable of 19.86 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Joyzyme Group and its competitors. This is 54% below median its historical median of 42.72. Over the past decade, Joyzyme Group's Days Payable has ranged from 22.35 to 60.76. According to the industry distribution chart, Joyzyme Group ranks #861 out of 925 companies in the Drug Manufacturers industry, placing it in the top 93.1%.
Is Joyzyme Group's Days Payable too high?
Joyzyme Group's current Days Payable of 19.86 is 54% below median its 10-year median of 42.72. Over the past 10 years, this metric has ranged from a low of 22.35 to a high of 60.76. The Drug Manufacturers industry median Days Payable is 88.85. Joyzyme Group's value of 19.86 is 77.6% below this industry median. Based on the distribution chart, Joyzyme Group ranks #861 out of 925 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Joyzyme Group has a GF Score™ of 40/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Joyzyme Group's Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Joyzyme Group ranks #861 out of 925 companies for Days Payable. This places Joyzyme Group in the lower half of its industry. The industry median Days Payable is 88.85. Joyzyme Group's value of 19.86 is 77.6% below this benchmark. Historically, Joyzyme Group's own Days Payable has ranged from 22.35 to 60.76 over the past decade. While the company's 10-year median is 42.72 vs. the industry median of 88.85, Joyzyme Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 88.85, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Joyzyme Group's current Days Payable of 19.86 is 77.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Joyzyme Group and its competitors. For the Drug Manufacturers industry, the median Days Payable is 88.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Joyzyme Group's current Days Payable is 19.86, which is 54% below median its own 10-year median of 42.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Joyzyme Group stock overvalued right now?
Based on GuruFocus' analysis, Joyzyme Group (HKSE:08622) is currently considered Fairly Valued. The stock's GF Value™ is HK$0.17, compared to a current price of HK$0.17 — trading 2.9% below its estimated fair value. The current Days Payable is 19.86, which is 54% below median its 10-year median of 42.72 and 77.6% below the Drug Manufacturers industry median of 88.85. Joyzyme Group's overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Joyzyme Group (HKSE:08622), the current Days Payable is 19.86 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Joyzyme Group (HKSE:08622) Overvalued in 2026?
Based on GuruFocus' analysis, Joyzyme Group stock appears to be undervalued.
The current stock price of HK$0.17 is trading 2.9% below its estimated GF Value™ of HK$0.17.
GuruFocus considers Joyzyme Group to be Fairly Valued.
Key valuation signals for HKSE:08622:
Days Payable: 19.86 (54% below median its 10-year median of 42.72)
GF Value™: HK$0.17 vs. price of HK$0.17 (2.9% below fair value)
Industry Position: 77.6% below the Drug Manufacturers median (#861 of 925)
No single metric tells the full story. See the HKSE:08622 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AddressNo.16 Yinkui Road, 1-3 floor and 5th floor, Building D, Shenzhen Junxuan, Kui Xin Community, Kui Chong Office, Dapeng New District, Shenzhen, CHN
Joyzyme Group Ltd is an investment holding company. The Company and its subsidiaries are principally engaged in research and development, manufacture, marketing, and sale of biological reagents and auxiliary reproductive supplies and equipment, and healthcare products and supplements in the People's Republic of China (the PRC). It operates in two segments: Biological reagents and auxiliary reproductive supplies and equipment, and Healthcare products and supplements. It generates the majority of its revenue from the biological reagents and auxiliary reproductive supplies and equipment segment. Geographically, it generates revenue from the PRC.
40GF Score
Get the complete analysis for HKSE:08622
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08622 has been successfully added to your 
